An opportunity has arisen for accredited investors as defined in Rule 501(a) of Regulation D of the US Securities Act of 1933, to register interest in an investment through a Fund into InSightec Ltd., (the “Issuer”) a private company operating in Israel and the USA. www.insightec.com.
INSIGHTEC is a global medical technology innovator with a vision to transform healthcare by making incisionless MR-guided focused ultrasound (MRgFUS) a standard of care for patients. Focused ultrasound technology uses sound waves that pass safely through skin, bone, and muscle. The spot where the sound waves converge is heated to temperatures that cause thermal ablation. When paired with MR imaging, a complete anatomical survey of the treatment area allows for patient-specific planning and real-time monitoring.
The company's award-winning Exablate NeuroTM device is FDA-approved to treat medication-refractory essential tremor and tremor-dominant Parkinson's disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Tokyo and Shanghai.
The Fund is currently in negotiations to purchase up to $10,000,000 of units in investment vehicles holding shares of the Issuer’s Preferred Stock and is exploring additional opportunities to purchase shares and/or interests in investment vehicles holding or acquiring shares. The Fund is also monitoring InSightec’s plans to issue up to an additional $50,000,000 of its Series F Preferred Stock.
Such issuance has been authorised by InSightec but it has not revealed any plans it might have to issue and sell such additional shares.
You can also see a number of media articles relating to InSightec by clicking the Documents tab.
To receive further information and be connected to the advisor, Register Interest.